Celldex Therapeutics, Inc. (CLDX)

41,06 -0,15 (-0,36%) Börsenschluss: 04:00PM EDT

Celldex Therapeutics, Inc.

Perryville III Building
Suite 220 53 Frontage Road
Hampton, NJ 08827
United States
908 200 7500
https://www.celldex.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 160

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Anthony S. Marucci M.B.A.	Founder, President, CEO & Director	1,27M	N/A	1962
Dr. Tibor Keler Ph.D.	Founder, Chief Scientific Officer & Executive VP	810,39k	N/A	1959
Mr. Sam Martin	Senior VP, CFO, Secretary & Treasurer	676,87k	N/A	1971
Dr. Margo Heath-Chiozzi M.D.	Senior Vice President of Regulatory Affairs	667,21k	N/A	1957
Dr. Diane C. Young M.D.	Senior VP & Chief Medical Officer	696,45k	N/A	1957
Prof. Joseph P. Schlessinger Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1945
Ms. Sarah Cavanaugh	Senior Vice President of Corporate Affairs & Administration	N/A	N/A	1975
Mr. Freddy A. Jimenez Esq.	Senior VP & General Counsel	579,7k	N/A	1969
Dr. Ronald A. Pepin	Chief Business Officer & Senior VP	441,84k	N/A	1956
Ms. Elizabeth Crowley	Chief Product Development Officer & Senior VP	507,24k	N/A	1972

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Corporate Governance

Celldex Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 1. Die grundlegenden Scores sind Audit: 2, Vorstand: 2, Shareholderrechte: 1, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.